CYP2C19功能缺失等位基因与抗抑郁药处方者胃肠道出血风险无关:英国南亚裔队列分析
结论认为仅依据CYP2C19基因信息进行精准剂量调整不太可能降低GIB发生率。
要点
- 在处方抗抑郁药者中,CYP2C19慢代谢或中间代谢状态与GIB无显著关联。
- 仅基于CYP2C19基因的精准 dosing 不太可能降低GIB发生率。
核心结论
- CYP2C19依赖性抗抑郁药与胃肠道出血患病率增加相关。
- 在处方抗抑郁药个体中,GIB似乎独立于CYP2C19代谢者基因型。
- 仅基于CYP2C19遗传信息的精准剂量调整不太可能降低GIB患病率。
研究设计与样本
- 评估CYP2C19双体型并根据联盟指南推断代谢者类型。
- 使用Fisher精确检验比较不同代谢者类别间GIB患病率,并用多变量回归检验关联。
主要发现
- 864名参与者(4%)发生GIB;其中534名(62%)曾被处方CYP2C19代谢型抗抑郁药。
- 在处方抗抑郁药者中,未调整分析显示CYP2C19推断的慢代谢(P=0.56)或中间代谢(P=0.53)状态与GIB无关联。
- 多变量逻辑回归模型未显示处方抗抑郁药亚组中CYP2C19慢代谢(P=0.54)或中间代谢(P=0.62)与GIB的独立关联。
临床怎么用
- 临床应关注抗抑郁药处方者的GIB风险,但不应仅依赖CYP2C19基因型来预测或预防GIB。
- 对于南亚裔患者,CYP2C19代谢状态可能不改变抗抑郁药相关GIB的风险评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: CYP2C19 is a hepatic enzyme involved in the metabolism of antidepressants associated with increased gastrointestinal bleed (GIB) risk. The aim of our study was to explore a possible association between loss-of-function CYP2C19 genotypes and GIB in South Asian ancestry participants prescribed antidepressants. METHODS: Genes & Health participants with a record in Barts Health NHS Trust (N 22 753) were studied using a cross-sectional approach. CYP2C19 diplotypes were assessed and metabolizer type inferred from consortia guidance. Fisher's exact test was used to compare the prevalence of GIB in different metabolizer categories. Multivariable regression was used to test for association between antidepressant prescriptions and GIB, and between CYP2C19 metabolizer state and GIB in the subcohort prescribed antidepressants. RESULTS: Antidepressants were frequently prescribed (47%, N = 10 612). A total of 864 participants (4%) had a GIB; 534 (62%) had been prescribed a CYP2C19 metabolized antidepressant. There was an independent association between antidepressant prescriptions and GIB events (odds ratio 1.8, confidence interval 1.5-2.0, P < 0.0001). There was no relationship between CYP2C19 inferred poor (P 0.56) or intermediate (P 0.53) metabolizer status and GIB in those prescribed an antidepressant in unadjusted analysis. A multivariable logistic regression model did not show an independent association between poor (P 0.54) or intermediate (P 0.62) CYP2C19 metabolizers and GIB in the subcohort prescribed antidepressants. CONCLUSIONS: CYP2C19 dependent antidepressants are associated with increased GIB prevalence. GIB appeared independent from CYP2C19 metabolizer genotype in individuals who had been prescribed antidepressants. Precision dosing based on CYP2C19 genetic information alone is unlikely to reduce GIB prevalence.
引用
- Magavern EF, van Heel DA, Smedley D, et al. CYP2C19 loss-of-function alleles are not associated with higher prevalence of gastrointestinal bleeds in those who have been prescribed antidepressants: Analysis in a British-South Asian cohort. Br J Clin Pharmacol. 2023. PMID: 37143396. doi:10.1111/bcp.15762
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。